The recent success of kinase inhibitors targeting the B cell receptor downstream molecules BTK (ibrutinib and PI3K (idelalisib), their characteristic clinical activity with chronic lymphocytic leukemia (CLL) cell redistribution from tissues into the blood, and their unique mechanism, interception of critical CLL - microenvironment interactions and signaling pathways, emphasize that the CLL microenvironment is a critical player in CLL pathogenesis and key for development of new targeted treatment approaches.
|Title of host publication||Hodgkin and Non-Hodgkin Lymphomas Seen through Their Microenvironment: Impact on Diagnosis, Prognosis and Innovative Therapy|
|Publisher||Future Medicine Ltd.|
|Number of pages||16|
|ISBN (Print)||9781780845821, 9781780845845|
|Publication status||Published - Jun 1 2015|
ASJC Scopus subject areas